Salvage chemotherapy with carboplatin plus weekly docetaxel in patients (pts) with castration- and docetaxel-resistant prostate cancer (DRPC): Associations of patient and disease characteristics with overall survival (OS).
Christoph W. Reuter
No relevant relationships to disclose
Michael A. Morgan
No relevant relationships to disclose
Viktor Grünwald
No relevant relationships to disclose
Christoph A. J. von Klot
No relevant relationships to disclose
Axel S. Merseburger
No relevant relationships to disclose
Philipp Ivanyi
No relevant relationships to disclose
Martin Fenner
No relevant relationships to disclose
Arnold Ganser
No relevant relationships to disclose